X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
danirixin (10) 10
chronic obstructive pulmonary disease (6) 6
cxcr2 antagonist (5) 5
humans (5) 5
index medicus (5) 5
pharmacology & pharmacy (4) 4
aged (3) 3
gsk1325756 (3) 3
male (3) 3
neutrophils (3) 3
administration, oral (2) 2
age factors (2) 2
chemokines (2) 2
copd (2) 2
cross-over studies (2) 2
cxcr2 (2) 2
female (2) 2
glaxosmithkline (2) 2
healthy volunteers (2) 2
immunology (2) 2
infectious diseases (2) 2
influenza (2) 2
major (2) 2
major articles (2) 2
metabolite (2) 2
microbiology (2) 2
neutrophil (2) 2
pharmacokinetics (2) 2
pharmacology (2) 2
piperidines - administration & dosage (2) 2
piperidines - adverse effects (2) 2
piperidines - blood (2) 2
piperidines - chemistry (2) 2
piperidines - pharmacokinetics (2) 2
research (2) 2
safety (2) 2
selective antagonist (2) 2
selective cx chemokine receptor 2 antagonist (2) 2
sulfones - administration & dosage (2) 2
sulfones - adverse effects (2) 2
sulfones - blood (2) 2
sulfones - chemistry (2) 2
sulfones - pharmacokinetics (2) 2
the copd pipeline (2) 2
absorption (1) 1
acos (1) 1
adolescent (1) 1
adult (1) 1
aged, 80 and over (1) 1
antagonist (1) 1
antagonist drugs (1) 1
anti-inflammatory agents, non-steroidal - adverse effects (1) 1
anti-inflammatory agents, non-steroidal - pharmacokinetics (1) 1
anti-inflammatory agents, non-steroidal - pharmacology (1) 1
aspirin (1) 1
azd5069 (1) 1
azd8871 (1) 1
bioavailability (1) 1
biological availability (1) 1
biomedicine (1) 1
case studies (1) 1
cd11b antigen - blood (1) 1
cell migration (1) 1
cells (1) 1
cellular signal transduction (1) 1
chemistry, pharmaceutical (1) 1
chemokine cxcl1 - antagonists & inhibitors (1) 1
chemokine cxcl1 - pharmacology (1) 1
chemokine receptor antagonist (1) 1
chemokine receptors (1) 1
chemoprophylaxis (1) 1
chf6333 (1) 1
cxc chemokine receptor 2 (1) 1
cxc chemokine receptor 2 antagonist (1) 1
cxcr1/cxcr2 antagonist (1) 1
danirixin hydrobromide (1) 1
design (1) 1
devices (1) 1
disproportionation (1) 1
dissolution (1) 1
dosage and administration (1) 1
dose-response relationship, drug (1) 1
double-blind method (1) 1
drug interactions (1) 1
drug pipeline (1) 1
drug therapy (1) 1
drug-interactions (1) 1
england (1) 1
excipients (1) 1
fasting - blood (1) 1
food - adverse effects (1) 1
formulation development (1) 1
gastric mucosa - drug effects (1) 1
gastric mucosa - metabolism (1) 1
gastroesophageal-reflux disease (1) 1
gastroplus (1) 1
gsk2269557 (1) 1
hematology (1) 1
high performance liquid chromatography (1) 1
hospitalization (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Current Opinion in Hematology, ISSN 1065-6251, 01/2019, Volume 26, Issue 1, pp. 28 - 33
PURPOSE OF REVIEWCXCR2 is key stimulant of immune cell migration and recruitment, especially of neutrophils. Alleviating excessive neutrophil accumulation and... 
MIGRATION | CELLS | infection | MARROW | MOBILIZATION | TRAFFICKING | CXCR2 antagonist | AZD5069 | NEUTROPHIL RECRUITMENT | CXCR1/CXCR2 ANTAGONIST | inflammation | CXCR2 | DANIRIXIN | CHEMOKINE RECEPTORS | HEMATOLOGY | neutrophils | Cellular signal transduction | Inflammation | Research | Cell migration | Chemokine receptors | Neutrophils
Journal Article
OPEN FORUM INFECTIOUS DISEASES, ISSN 2328-8957, 04/2019, Volume 6, Issue 4, p. ofz163
Background. Excessive neutrophil migration has been correlated with influenza symptom severity. Danirixin (GSK1325756), a selective and reversible antagonist... 
influenza | danirixin | INFECTIOUS DISEASES | ANTAGONIST | hospitalization | CXCR2 | CXCR2 antagonist | MICROBIOLOGY | OUTCOMES | IMMUNOLOGY | neutrophils
Journal Article
OPEN FORUM INFECTIOUS DISEASES, ISSN 2328-8957, 04/2019, Volume 6, Issue 4, p. ofz072
Background. Danirixin (DNX), a selective and reversible CXC chemokine receptor 2 antagonist, inhibits neutrophil transmigration and activation. This study... 
influenza | INFECTIOUS DISEASES | SELECTIVE ANTAGONIST | NEUTROPHILS | MICROBIOLOGY | IMMUNOLOGY | outpatient | INTERLEUKIN-8 | RECOMMENDATIONS | safety | danirixin (DNX) | CHEMOPROPHYLAXIS | CXC chemokine receptor 2 (CXCR2) antagonist
Journal Article
Journal Article
Clinical Pharmacology in Drug Development, ISSN 2160-763X, 11/2019, Volume 8, Issue 8, pp. 1081 - 1087
Danirixin is a selective and reversible CXC chemokine receptor 2 antagonist that may be useful for the treatment of respiratory diseases such as chronic... 
pharmacokinetics | danirixin hydrobromide | CXC chemokine receptor 2 | tolerability and safety | chronic obstructive pulmonary disease | SELECTIVE ANTAGONIST | CXCR2 ANTAGONIST | PHARMACOLOGY & PHARMACY | Index Medicus
Journal Article
BMC Pharmacology and Toxicology, ISSN 2050-6511, 06/2015, Volume 16, Issue 1, pp. 18 - 18
Journal Article
European Journal of Drug Metabolism and Pharmacokinetics, ISSN 0378-7966, 9/2014, Volume 39, Issue 3, pp. 173 - 181
Journal Article
Chronic Obstructive Pulmonary Diseases, ISSN 2372-952X, 2018, Volume 5, Issue 1, pp. 66 - 71
Journal Article
Chronic obstructive pulmonary diseases (Miami, Fla.), ISSN 2372-952X, 07/2015, Volume 2, Issue 3, pp. 259 - 263
Journal Article
09/2016, ISBN 9781118949658, 17
All glaxosmithkline (GSK)‐sponsored studies referred to were conducted in accordance with the guiding principles of the Declaration of Helsinki and in... 
danirixin | metabolite | glaxosmithkline | selective CX chemokine receptor 2 antagonist | humans | chronic obstructive pulmonary disease
Book Chapter
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.